Clinical Trials Logo

Healthy clinical trials

View clinical trials related to Healthy.

Filter by:

NCT ID: NCT04610203 Completed - Healthy Clinical Trials

Glycaemic Response, Insulinaemic Response, GLP-1 and GIP Testing of Food Product Lines

Start date: December 3, 2018
Phase: N/A
Study type: Interventional

The aim of this study was to compare the glycaemic response, insulinaemic response, GIP response and GLP-1 response to glucose, 25 g Nutralys S85 Plus and 50 g Nutralys S85 Plus using a single-blind, randomised, repeat measure, crossover design trial.

NCT ID: NCT04610151 Completed - Healthy Clinical Trials

The Effects of Guided Imagery on Postoperative Pain Management

Start date: April 1, 2018
Phase: N/A
Study type: Interventional

This study was conducted to determine the effects of guided imagery on postoperative pain management.

NCT ID: NCT04609696 Completed - Healthy Clinical Trials

Study of the Metabolism of Danicopan in Healthy Adults

Start date: October 20, 2020
Phase: Phase 1
Study type: Interventional

This is a 2-part open-label, randomized, single-dose, 3-sequence, 3-period crossover, relative bioavailability, and food-effect study comparing different formulations of danicopan in healthy adult participants.

NCT ID: NCT04609670 Completed - Healthy Clinical Trials

Study of Radiolabeled ALXN2050 in Healthy Adult Males

Start date: April 12, 2021
Phase: Phase 1
Study type: Interventional

This is an open-label study to assess the absorption, metabolism, excretion, and mass balance of a single oral dose of carbon-14 ([14C])-ALXN2050 in healthy adult males.

NCT ID: NCT04608513 Completed - Healthy Clinical Trials

A Placebo-controlled Phase 1 Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-ascending Doses of ACT-1014-6470 in Healthy Subjects

Start date: November 16, 2020
Phase: Phase 1
Study type: Interventional

A safety and tolerability study in healthy subjects including examination of how the body takes up, distributes, and gets rid of ACT-1014-6470

NCT ID: NCT04607733 Completed - Healthy Clinical Trials

A Study of Mirikizumab in Healthy Participants

Start date: November 2, 2020
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to compare the amount of mirikizumab that gets into the blood stream and how long it takes the body to get rid of it, when given as a solution formulation via manual prefilled syringe or autoinjector. The information about any adverse effects experienced will be collected and the tolerability of mirikizumab will also be evaluated. Screening is required within 28 days prior to the start of the study. For each participant, the total duration of the clinical trial will be about 17 weeks, including screening.

NCT ID: NCT04606628 Completed - Healthy Clinical Trials

Optimal Value Increase of Egg Products

OPTIEgg
Start date: October 15, 2020
Phase: N/A
Study type: Interventional

The aim of this project is to evaluate daily intake of eggshell membrane taken as supplement (capsule), will reduce markers of inflammation in older people.

NCT ID: NCT04606537 Completed - Healthy Clinical Trials

Drug to Drug Interaction Study of KBP-5074 in Healthy Subjects

Start date: October 24, 2020
Phase: Phase 1
Study type: Interventional

Open-label, parallel, 2-arm, fixed-sequence study to investigate the effect of coadministration of a CYP3A4 inhibitor (Cohort 1, itraconazole multiple dose) and CYP3A4 inducer (Cohort 2, rifampin multiple dose) on the plasma PK of a single dose of KBP-5074 in healthy male and female subjects.

NCT ID: NCT04603378 Completed - Healthy Clinical Trials

A Clinical Study to Assess the Effect of Novel Glycans on Nitrogen Metabolism of the Gut in Healthy Subjects

Start date: September 18, 2017
Phase: N/A
Study type: Interventional

This exploratory, randomized, double-blind, placebo-controlled study aims to explore the effect of novel glycans on nitrogen metabolism in the gut in healthy subjects using a stable isotope.

NCT ID: NCT04602975 Completed - Healthy Clinical Trials

A Study to Investigate the Safety and Immunogenicity of the SF2a-TT15 Synthetic Carbohydrate-based Conjugate Vaccine Against Shigella Flexneri 2a

GlycoShig3
Start date: October 6, 2020
Phase: Phase 2
Study type: Interventional

A study among adults, children and infants in Kenya to determine if a new type of glycoconjugate vaccine incorporating a synthetic carbohydrate component is safe and induces immunity against Shigella.